- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02222818
Cardiac Resynchronization Therapy Efficacy Enhancements (CRTee)
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The CRTee study is an IDE, prospective, multi-center, randomized, controlled, crossover clinical study, conducted worldwide and designed to demonstrate that the amount of effective CRT pacing during AF (atrial fibrillation) when CAFRPlus (Conducted AF Response Plus) is applied is not inferior to the amount of effective CRT pacing during AF when CAFR (Conducted AF Response) is applied.
The study will be conducted at up to 30 centers located in the United States, Europe and Middle East and Africa (MEA).
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Riyadh, Arabia Saudita
- Prince Sultan Cardiac Center
-
-
-
-
-
Roma, Italia
- Policlinico Universitario Agostino Gemelli
-
Seriate, Italia
- Azienda Ospedaliera Bolognini Seriate - Ospedale Bolognini
-
Tricase, Italia
- Azienda Ospedaliera Cardinale Panico
-
-
-
-
-
Liverpool, Regno Unito
- Liverpool Heart and Chest Hospital NHS Foundation Trust
-
Newcastle Upon Tyne, Regno Unito
- he Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital
-
-
-
-
-
Kosice, Slovacchia
- Východoslovenský Ústav Srdcových A Cievnych Chorôb, A.S.
-
-
-
-
Florida
-
Boca Raton, Florida, Stati Uniti
- Cardiac Arrythmia Services
-
-
Iowa
-
West Des Moines, Iowa, Stati Uniti
- Iowa Heart Center
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti
- North Memorial Heart and Vascular
-
St. Cloud, Minnesota, Stati Uniti
- CentraCare
-
-
North Carolina
-
Raleigh, North Carolina, Stati Uniti
- North Carolina Heart and Vascular
-
-
Ohio
-
Columbus, Ohio, Stati Uniti
- Mount Carmel
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti
- Oklahoma Heart
-
-
Pennsylvania
-
Reading, Pennsylvania, Stati Uniti
- Berks Cardiology
-
-
Texas
-
Austin, Texas, Stati Uniti, 78705
- Texas Cardiac Arrhythmia Services
-
-
Washington
-
Spokane, Washington, Stati Uniti
- Kootenai Heart Clinics
-
-
-
-
-
Cape Town, Sud Africa
- Mediclinic Panorama
-
-
-
-
-
Budapest, Ungheria
- Magyar Honvédség Honvédkorház
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Subject is willing to sign and date the study patient Informed Consent form.
- Subject is at least 18 years of age (or older, if required by local law).
- Subject is expected to remain available after enrollment to complete follow-up visits in both arms of the study
- Subject has had a Medtronic Viva or Brava CRT-D device implanted at least 30 days prior to enrollment.
- Subject has history of AF burden, of at least 6 days of at least 4 hours of AF over any 4 week period within the last 90 days as documented in device diagnostic data OR if subject has no atrial lead (therefore no device diagnostic data) but clinical evidence of high AF burden.
- Subject has demonstrated history of being able to complete Left Ventricular Capture Management (LVCM) documented in device data.
- Subject has a documented % V pacing during AF of less than or equal to 97% within 90 days prior to enrollment or within 10 days after enrollment.
Exclusion Criteria:
- Subject has undergone AV node ablation for treatment of AF.
- Subject has complete or 3rd degree AV block.
- Subject has had an MI within 30 days.
- Subject has medical conditions that limit study participation (per physician discretion).
- Subject is enrolled in one or more concurrent studies that could confound the study results as determined by Medtronic.
- Subject has a limited life expectancy for non-cardiac causes that would not allow completion of the study.
- Subject is pregnant (in the US, all women of child-bearing potential must undergo a pregnancy test within seven days prior to CRTee download).
- Subject meets the exclusion criteria required by local law.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Altro: Group A: CAFR first
Subjects randomized to Group A will receive CAFR first, then cross over to CAFRPlus.
|
The CAFR algorithm is currently available in the Medtronic market-released devices and intended to promote delivery of CRT pacing during conducted AT/AF episodes.
The CAFRPlus algorithm is part of the CRTee feature set.
This feature set has a diagnostic element that tracks the loss of effective CRT pacing that is occurring over time, both during normal sinus rhythm (NSR) and during AF.
It also has an interventional element (i.e.
CAFRPlus) that uses this evaluation of effective CRT pacing to adjust the pacing rate during AF to decrease loss of effective CRT pacing.
|
Altro: Group B: CAFRPlus first
Subjects randomized to Group B will receive CAFRPlus first, then cross over to CAFR.
|
The CAFR algorithm is currently available in the Medtronic market-released devices and intended to promote delivery of CRT pacing during conducted AT/AF episodes.
The CAFRPlus algorithm is part of the CRTee feature set.
This feature set has a diagnostic element that tracks the loss of effective CRT pacing that is occurring over time, both during normal sinus rhythm (NSR) and during AF.
It also has an interventional element (i.e.
CAFRPlus) that uses this evaluation of effective CRT pacing to adjust the pacing rate during AF to decrease loss of effective CRT pacing.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Percentage of Effective CRT Pacing During AF (Non-inferiority Test)
Lasso di tempo: Up to 4 months
|
The primary objective is to demonstrate that the percent effective CRT pacing during AF when CAFRPlus is applied is not inferior to when CAFR is applied (non-inferiority test).
|
Up to 4 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Percentage of Effective CRT Pacing During AF (Superiority Test)
Lasso di tempo: Up to 4 months
|
The secondary objective is to demonstrate that the percent effective CRT pacing during AF when CAFRPlus is applied is greater than when CAFR is applied (superiority test).
|
Up to 4 months
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Suneet Mittal, MD, Valley Health System
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CRTee
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Conducted AF Response (CAFR)
-
Medtronic Bakken Research CenterMedtronicTerminatoArresto cardiaco | Fibrillazione atriale | Morte cardiaca improvvisaGermania